{"url_path":"/sec/nmtc/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1500198/0001213900-26-054749-index.html","accession_number":"0001213900-26-054749","cik":"0001500198","ticker":"NMTC","issuer_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1500198/0001213900-26-054749-index.html","primary_entity_key":"0001500198","primary_entity_name":"NEUROONE MEDICAL TECHNOLOGIES Corp"},"word_count":443,"has_tables":true,"body_markdown":"**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, DC 20549**\n\n \n\n**Form 10-Q**\n\n \n\n**(Mark One)**\n\n☒ QUARTERLY REPORT PURSUANT TO SECTION 13\nOR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\n**For the Quarterly Period Ended March 31, 2026**\n\n \n\n**OR**\n\n \n\n☐ TRANSITION REPORT PURSUANT TO SECTION 13\nOR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\n**For the transition period from ________ to ________**\n\n \n\nCommission File Number**: 001-40439**\n\n \n\n**NeuroOne Medical Technologies Corporation**\n\n(Exact name of Registrant as specified in its charter)\n\n \n\n**Delaware**   **27-0863354**\n\n(State or Other Jurisdiction of\n\nIncorporation or Organization)   (I.R.S. Employer\n\nIdentification Number)\n\n     \n\n**7599 Anagram Drive\nEden Prairie, MN**   **55344**\n\n(Address of Principal Executive Offices)   (Zip Code)\n\n \n\nRegistrant’s Telephone Number, Including\nArea Code: **952-426-1383**\n\n \n\n**Not Applicable**\n\n(Former name, former address and former fiscal year, if changed since last report)\n\n \n\nSecurities registered pursuant to Section 12(b)\nof the Act:\n\n \n\n**Title of Each Class**   **Trading Symbol(s)**   **Name of Each Exchange on Which Registered**\n\nCommon stock, $0.001 par value   NMTC   The Nasdaq Stock Market LLC\n\n \n\nIndicate by check mark whether the registrant\n(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months\n(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements\nfor the past 90 days. Yes ☒  No ☐\n\n \n\nIndicate by check mark whether the registrant\nhas submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (section 232.405\nof this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes\n☒  No ☐\n\n \n\nIndicate by check mark whether the registrant\nis a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.\nSee the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”,\nand “emerging growth company” in Rule 12b-2 of the Exchange Act:\n\n \n\nLarge accelerated filer ☐ Non-accelerated filer ☒\n\nAccelerated filer ☐ Smaller reporting company ☒\n\n    Emerging growth company ☐\n\n \n\nIf an emerging growth company, indicate by check\nmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting\nstandards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant\nis a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐  No ☒\n\n \n\nThe number of outstanding shares of the registrant’s\ncommon stock as of May 8, 2026 was 8,619,876.\n\n \n\n \n\n \n\n \n\n \n\n**NEUROONE MEDICAL TECHNOLOGIES CORPORATION**\n\n**FORM 10-Q**\n\n \n\n**INDEX**\n\n \n\n \n \n \n**Page**\n\n \n[PART 1 – FINANCIAL INFORMATION](#a_001)"}